Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012

523 views

Published on

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 Summary GlobalData's clinical trial report, 'Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012" provides data on the Focal Segmental Glomerulosclerosis (FSGS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Focal Segmental Glomerulosclerosis (FSGS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Focal Segmental Glomerulosclerosis (FSGS). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

  • Hi! Get Your Professional Job-Winning Resume Here! 👉 http://bit.ly/rexumtop
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Focal Segmental Glomerulosclerosis (FSGS) Global Clinical TrialsReview, H2, 2012Published on November 2012 Report SummaryFocal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012SummaryGlobalDatas clinical trial report, Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012" provides dataon the Focal Segmental Glomerulosclerosis (FSGS) clinical trial scenario. This report provides elemental information and data relatingto the clinical trials on Focal Segmental Glomerulosclerosis (FSGS). It includes an overview of the trial numbers and their recruitmentstatus as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by theirphase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs fortreating Focal Segmental Glomerulosclerosis (FSGS). This report is built using data and information sourced from proprietarydatabases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicateddisease.Scope- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa andAsia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)Reasons to buy- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Table of ContentTable of ContentsTable of Contents 2List of Tables 4List of Figures 5Introduction 6Focal Segmental Glomerulosclerosis (FSGS) 6Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 1/6
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Report Guidance 6Clinical Trials by Region 7Clinical Trials by Country 8Top Countries Contributing to Clinical Trials in Asia-Pacific 10Top Countries Contributing to Clinical Trials in Europe 11Top Countries Contributing to Clinical Trials in North America 12Top Countries Contributing to Clinical Trials in Middle East and Africa 13Top Countries Contributing to Clinical Trials in Central and South America 14Clinical Trials by BRIC Nations 15Clinical Trials by G7 Nations 16Clinical Trials in G7 Nations by Trial Status 17Clinical Trials by E7 Nations 18Clinical Trials in E7 Nations by Trial Status 19Clinical Trials by Phase 20In Progress Trials by Phase 21Clinical Trials by Trial Status 22Unaccomplished Trials of Focal Segmental Glomerulosclerosis (FSGS) 23Subjects Recruited Over a Period of Time 26Prominent Sponsors 27Top Companies Participating in Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials 29Prominent Drug Comparison 30Clinical Trial Profiles 31Clinical Trial Overview of Top Companies 31Genzyme Corporation 31Clinical Trial Overview of Genzyme Corporation 31Retrophin, LLC 32Clinical Trial Overview of Retrophin, LLC 32FibroGen, Inc. 33Clinical Trial Overview of FibroGen, Inc. 33Clinical Trial Overview of Top Universities / Institutes / Hospitals 34Nanjing University 34Clinical Trial Overview of Nanjing University 34Xian Jiaotong University College of Medicine 35Clinical Trial Overview of Xian Jiaotong University College of Medicine 35University of Tsukuba 36Clinical Trial Overview of University of Tsukuba 36Childrens Research Institute 37Clinical Trial Overview of Childrens Research Institute 37Guangdong General Hospital 38Clinical Trial Overview of Guangdong General Hospital 38Ruijin Hospital 39Clinical Trial Overview of Ruijin Hospital 39University Medical Centre Ljubljana 40Clinical Trial Overview of University Medical Centre Ljubljana 40Nanjing Medical University 41Clinical Trial Overview of Nanjing Medical University 41Columbia University 42Clinical Trial Overview of Columbia University 42Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 2/6
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!University of Sao Paulo 43Clinical Trial Overview of University of Sao Paulo 43New York University School of Medicine 44Clinical Trial Overview of New York University School of Medicine 44Sunnybrook Health Sciences Centre 45Clinical Trial Overview of Sunnybrook Health Sciences Centre 45Stanford University 46Clinical Trial Overview of Stanford University 46Five Key Clinical Profiles 47Appendix 73Abbreviations 73Definitions 73Research Methodology 75Secondary Research 75About GlobalData 76Contact Us 76Disclaimer 76Source 77List of TablesFocal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Zone, 2012* 7Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 8Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 9Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2012* 10Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Europe, Top Countries, 2012* 11Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, North America, Top Countries, 2012* 12Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2012* 13Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Central and South America, Top Countries, 2012* 14Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, BRIC Countries, 2012* 15Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, G7 Countries, 2012* 16Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 17Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, E7 Countries, 2012* 18Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 19Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Phase, 2012* 20Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials In Progress by Phase 2012* 21Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 22Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Suspended Clinical Trials, 2012* 23Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Withdrawn Clinical Trials, 2012* 24Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Terminated Clinical Trials, 2012* 25Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2006-2011 26Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 28Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 29Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 30Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Genzyme Corporation,2012* 31Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Retrophin, LLC, 2012* 32Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by FibroGen, Inc., 2012* 33Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 3/6
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nanjing University, 2012*34Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Xian Jiaotong UniversityCollege of Medicine, 2012* 35Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Tsukuba,2012* 36Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Childrens ResearchInstitute, 2012* 37Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Guangdong GeneralHospital, 2012* 38Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ruijin Hospital, 2012* 39Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Medical CentreLjubljana, 2012* 40Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nanjing Medical University,2012* 41Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2012*42Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo,2012* 43Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York UniversitySchool of Medicine, 2012* 44Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sunnybrook HealthSciences Centre, 2012* 45Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2012*46List of FiguresFocal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Zone (%), 2012* 7Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 8Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 9Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2012* 10Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Europe, Top Countries (%), 2012* 11Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, North America, Top Countries (%), 2012* 12Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, BRIC Countries (%), 2012* 15Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, G7 Countries (%), 2012* 16Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 17Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, E7 Countries (%), 2012* 18Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 19Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Phase (%), 2012* 20Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2012* 21Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 22Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2006-2011 26Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 27Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 29Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 30GlobalData Methodology 75Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 4/6
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 500.00 Quantity: _____ Site License--USD 5 000.00 Quantity: _____ Corporate License--USD 7 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 5/6
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 6/6

×